MACROGENICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $1.85M, a 45.17% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $2.43M, a 60.22% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $2.80M, a 37.25% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $3.34M, a 46.00% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $15.63M, a 13.11% decline from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $17.99M, a 9.47% increase from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $16.43M, a 16.03% decline from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $19.57M, a 3.10% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.29M 10-Q · filed 2026-08-14 | $7.08M derived: sum of 3 quarters · filed 2026-08-14 | $10.43M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $2.43M 10-Q · filed 2026-05-13 | $5.23M derived: sum of 2 quarters · filed 2026-05-13 | $8.57M derived: sum of 3 quarters · filed 2026-05-13 | $11.95M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.14M derived: sum of 2 quarters · filed 2026-03-09 | $9.52M derived: sum of 3 quarters · filed 2026-08-14 | $15.63M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.72M derived: sum of 2 quarters · filed 2026-08-14 | $12.84M 10-Q · filed 2025-11-12 | $17.30M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $3.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $9.49M 10-Q · filed 2026-08-14 | $13.95M derived: sum of 3 quarters · filed 2026-08-14 | $20.14M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $6.12M 10-Q · filed 2026-05-13 | $10.58M derived: sum of 2 quarters · filed 2026-05-13 | $16.77M derived: sum of 3 quarters · filed 2026-05-13 | $20.21M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $10.65M derived: sum of 2 quarters · filed 2026-03-09 | $14.09M derived: sum of 3 quarters · filed 2026-03-09 | $17.99M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $6.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.63M derived: sum of 2 quarters · filed 2025-11-12 | $13.53M 10-Q · filed 2025-11-12 | $16.36M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $7.34M 10-Q · filed 2025-08-14 | $10.17M derived: sum of 3 quarters · filed 2026-03-09 | $20.25M derived: sum of 4 quarters · filed 2026-03-09 | ||||
| 2024-03-31 | $3.90M 10-Q · filed 2025-05-13 | $3.90M 10-Q · filed 2024-05-09 | $6.73M derived: sum of 2 quarters · filed 2026-03-09 | $16.80M derived: sum of 3 quarters · filed 2026-03-09 | $15.94M derived: sum of 4 quarters · filed 2026-03-09 | |||
| 2023-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $12.90M derived: sum of 2 quarters · filed 2026-03-09 | $12.04M derived: sum of 3 quarters · filed 2026-03-09 | $16.43M 10-K · filed 2026-03-09 | $16.40M 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $10.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $9.21M derived: sum of 2 quarters · filed 2024-11-05 | $13.61M 10-Q · filed 2024-11-05 | $13.60M 10-Q · filed 2023-11-06 | $18.08M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-06-30 | -$867.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.53M 10-Q · filed 2024-08-06 | $3.50M 10-Q · filed 2023-08-09 | $8.01M derived: sum of 3 quarters · filed 2025-03-20 | $13.71M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2023-03-31 | $4.40M 10-Q · filed 2024-05-09 | $600.00K 10-Q · filed 2023-05-09 | $8.87M derived: sum of 2 quarters · filed 2025-03-20 | $14.57M derived: sum of 3 quarters · filed 2025-03-20 | $18.57M derived: sum of 4 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $10.17M derived: sum of 2 quarters · filed 2025-03-20 | $14.17M derived: sum of 3 quarters · filed 2025-03-20 | $19.57M 10-K · filed 2025-03-20 | $19.60M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $9.70M derived: sum of 2 quarters · filed 2023-11-06 | $15.10M 10-Q · filed 2023-11-06 | $20.50M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2022-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $9.40M 10-Q · filed 2023-08-09 | $14.80M derived: sum of 3 quarters · filed 2024-03-07 | $21.50M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2022-03-31 | $5.40M 10-Q · filed 2023-05-09 | $10.80M derived: sum of 2 quarters · filed 2024-03-07 | $17.50M derived: sum of 3 quarters · filed 2024-03-07 | $21.50M derived: sum of 4 quarters · filed 2024-03-07 | ||||
| 2021-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $12.10M derived: sum of 2 quarters · filed 2024-03-07 | $16.10M derived: sum of 3 quarters · filed 2024-03-07 | $20.20M 10-K · filed 2024-03-07 | ||||
| 2021-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $10.70M derived: sum of 2 quarters · filed 2022-11-03 | $14.80M 10-Q · filed 2022-11-03 | $19.10M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2021-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $8.10M 10-Q · filed 2022-08-08 | $12.40M derived: sum of 3 quarters · filed 2023-03-15 | $17.40M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2021-03-31 | $4.10M 10-Q · filed 2022-05-03 | $8.40M derived: sum of 2 quarters · filed 2023-03-15 | $13.40M derived: sum of 3 quarters · filed 2023-03-15 | $17.10M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2020-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $9.30M derived: sum of 2 quarters · filed 2023-03-15 | $13.00M derived: sum of 3 quarters · filed 2023-03-15 | $16.70M 10-K · filed 2023-03-15 | ||||
| 2020-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $8.70M derived: sum of 2 quarters · filed 2021-11-02 | $12.40M 10-Q · filed 2021-11-02 | $17.30M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $7.40M 10-Q · filed 2021-07-29 | $12.30M derived: sum of 3 quarters · filed 2022-02-24 | $18.60M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $3.70M 10-Q · filed 2021-04-29 | $8.60M derived: sum of 2 quarters · filed 2022-02-24 | $14.90M derived: sum of 3 quarters · filed 2022-02-24 | $18.30M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $11.20M derived: sum of 2 quarters · filed 2022-02-24 | $14.60M derived: sum of 3 quarters · filed 2022-02-24 | $17.70M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $9.70M derived: sum of 2 quarters · filed 2020-11-04 | $12.80M 10-Q · filed 2020-11-04 | $17.30M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $6.50M 10-Q · filed 2020-07-31 | $11.00M derived: sum of 3 quarters · filed 2021-02-25 | $16.60M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $3.10M 10-Q · filed 2020-05-05 | $7.60M derived: sum of 2 quarters · filed 2021-02-25 | $13.20M derived: sum of 3 quarters · filed 2021-02-25 | $19.50M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.10M derived: sum of 2 quarters · filed 2021-02-25 | $16.40M derived: sum of 3 quarters · filed 2021-02-25 | $16.40M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $11.90M derived: sum of 2 quarters · filed 2019-11-06 | $11.90M 10-Q · filed 2019-11-06 | $19.10M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $6.30M 10-Q · filed 2019-07-31 | $6.30M 10-Q · filed 2018-08-07 | $13.50M derived: sum of 3 quarters · filed 2020-02-25 | $18.10M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $3.30M 10-Q · filed 2019-05-01 | $7.20M derived: sum of 2 quarters · filed 2020-02-25 | $11.80M derived: sum of 3 quarters · filed 2020-02-25 | $14.80M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $8.50M derived: sum of 2 quarters · filed 2020-02-25 | $11.50M derived: sum of 3 quarters · filed 2020-02-25 | $14.60M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $7.60M derived: sum of 2 quarters · filed 2017-11-08 | $10.70M 10-Q · filed 2017-11-08 | $13.50M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $6.10M 10-Q · filed 2017-08-02 | $8.90M derived: sum of 3 quarters · filed 2019-02-26 | $11.70M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $3.10M 10-Q · filed 2017-05-03 | $5.90M derived: sum of 2 quarters · filed 2019-02-26 | $8.70M derived: sum of 3 quarters · filed 2019-02-26 | $12.70M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $5.60M derived: sum of 2 quarters · filed 2019-02-26 | $9.60M derived: sum of 3 quarters · filed 2019-02-26 | $11.60M 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $6.80M derived: sum of 2 quarters · filed 2016-11-02 | $8.80M 10-Q · filed 2016-11-02 | $11.20M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $6.00M 10-Q · filed 2016-08-03 | $8.40M derived: sum of 3 quarters · filed 2018-02-27 | $10.00M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $2.00M 10-Q · filed 2016-05-04 | $4.40M derived: sum of 2 quarters · filed 2018-02-27 | $6.00M derived: sum of 3 quarters · filed 2018-02-27 | $8.50M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.00M derived: sum of 2 quarters · filed 2018-02-27 | $6.50M derived: sum of 3 quarters · filed 2018-02-27 | $7.30M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $4.10M derived: sum of 2 quarters · filed 2015-11-04 | $4.90M 10-Q · filed 2015-11-04 | $5.90M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $3.30M 10-Q · filed 2015-08-05 | $4.30M derived: sum of 3 quarters · filed 2017-02-28 | $5.00M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $800.00K 10-Q · filed 2015-05-06 | $1.80M derived: sum of 2 quarters · filed 2017-02-28 | $2.50M derived: sum of 3 quarters · filed 2017-02-28 | $3.61M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $1.70M derived: sum of 2 quarters · filed 2017-02-28 | $2.81M derived: sum of 3 quarters · filed 2017-02-28 | $3.00M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.81M derived: sum of 2 quarters · filed 2014-11-12 | $2.00M 10-Q · filed 2014-11-12 | |||||
| 2014-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $1.30M 10-Q · filed 2014-08-05 | ||||||
| 2014-03-31 | $192.17K 10-Q · filed 2014-05-06 | |||||||
| 2013-12-31 | $500.00K 10-K · filed 2016-02-29 | $487.60K 10-K · filed 2014-03-20 | ||||||
| 2012-12-31 | $879.02K 10-K · filed 2015-03-03 | |||||||
| 2011-12-31 | $1.11M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |